The hormone replacement therapy (HRT) of menopause: Focus on cardiovascular implications

Acta Biomedica

Volumn 81, Issue SUPPL. 1, 2010, Pages 73-76

  Denti, Licia ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Cardiovascular risk; Hormone replacement therapy (HRT); Menopause

Indexed keywords

AGE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; METHODOLOGY; STROKE; VENOUS THROMBOEMBOLISM;

AGE FACTORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; STROKE; VENOUS THROMBOEMBOLISM;

EID: 77954915993     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (Heart and Estrogen/ progestin Replacement Study (HERS) Research Group). JAMA 1998; 280: 605-13
2. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002; 360: 2001-8.
3. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogens plus progestins in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
4. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357-65.
5. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007: 335: 239-51.
6. Sare JM, Gray LJ, Bath PMW. Association between Hormone Replacement Therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29: 2031-41.
7. Canonico M, Plu-Bureauu G, Lowe GDO, Scarabin P. Hormone replacement therapy and venous thromboembolism in postmenopausal women: systematic review and metaanalysis. BMJ 2008; 336: 1227-31.
8. Grodstein F, Manson JE, Colditz GA, et al. A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease. Ann Intern Med 2000; 133: 933-41.
9. Rossouw JR, Prentice RL, Manson JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA 2007; 297: 1465-77.
10. Arnal J-F, Gourdy P, Elhage R, et al. Estrogens and atherosclerosis. Eur J End 2004; 150; 113-7.
11. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obs Gynecol 2004; 190: 1141-67.
12. Barrett-Connor E, Mosca D, Collins P. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women. N Engl J Med 2006; 355: 125-37.
13. Barrett-Connor E, Cauley JA, Kulkarn PM, Sashegyi A, Cox DA, Geiger MJ. Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial. J Bone Min Res 2004; 19: 1270-5.
14. Mosca L, Grady D, Barrett-Connor E, et al. Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease. Stroke 2009;40;147-155.
15. Mosca L, Banka CL, Benjamin EJ et al. 2007 Update Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 update. Circulation 2007; 115; 1481-501.
16. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15: 147-55.